MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery

Completed · Not applicable · Has a placebo group

Conditions studied: Post Procedural Constipation

In brief

A. Purpose To compare MiraLAX versus placebo for preventing constipation in the immediate postoperative period following pelvic reconstructive surgery in women taking routine docusate sodium. B. Objectives 1. Specific Aims Specific Aim 1: To compare time to first bowel movement (BM) between MiraLAX versus placebo in women receiving routine docusate sodium after pelvic reconstructive surgery. Specific Aim 2: To compare patient reported outcomes of BM quality and associated gastrointestinal (GI) symptoms between MiraLAX versus placebo using the Bristol stool scale and the validated Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) in women receiving routine docusate sodium after pelvic reconstructive surgery. Specific Aim 3: To evaluate GI-related quality of life between MiraLAX versus placebo utilizing the validated Patient Assessment of Constipation Quality-of-Life Questionnaire (PAC-QOL) in women receiving routine docusate sodium after pelvic reconstructive surgery. 2. Hypotheses The investigators hypothesize that MiraLAX will optimally prevent constipation following pelvic reconstructive surgery by decreasing time to first BM, decreasing GI symptoms associated with constipation, and increasing measures of GI-related quality of life, while minimizing the bothersome side effects associated with stimulant laxatives.

Key facts

Study ID

NCT01691742

Run by

Duke University

People needed

131

Starts

2012-09-01

Expected to finish

2015-04-01

Last updated by the study team

2017-02-15

Who can join

Age: 19 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• English-speaking female patients
• > 18 years of age
• Not pregnant (patients of childbearing potential will have a serum pregnancy test done pre-operatively as part of their surgical planning)
• Undergoing surgery for pelvic organ prolapse or stress urinary incontinence
• Recruited from the Duke University Division of Urogynecology

You may not qualify if…

• Allergy/hypersensitivity to study medications
• Cardiac or renal disease
• Takes chronic daily laxatives
• Excluded if unable to complete at least 5 days of a 7 day baseline bowel diary
• Excluded if mesh resection or Interstim procedure
• Excluded if concurrent surgery includes anal sphincteroplasty or rectovaginal fistula repair

Where it is running

• Duke University, Department of Urogynecology — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.